



BOB RILEY  
Governor

# Alabama Medicaid Agency

501 Dexter Avenue  
P.O. Box 5624  
Montgomery, Alabama 36103-5624

www.medicaid.alabama.gov  
e-mail: [almedicaid@medicaid.alabama.gov](mailto:almedicaid@medicaid.alabama.gov)

Telecommunication for the Deaf: 1-800-253-0799  
334-242-5000 1-800-362-1504



CAROL H. STECKEL, MPH  
Commissioner

September 20, 2010

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with formal written notification of an upcoming meeting of the Alabama Medicaid Pharmacy & Therapeutics (P&T) Committee, to be held on **Wednesday, November 10, 2010**. This meeting may involve review of one or more of your company's drug products. Please note: this meeting will be held in the Commissioner's Board Room at the Alabama Medicaid Building located in Montgomery, Alabama and will begin at 9:00 a.m. All meetings of this committee are open to the public.

The following is a list of drug classes for review at this meeting:

Drug Class REVIEWS	
1. Central Alpha-Agonists – AHFS 240816	10. Angiotensin II Receptor Antagonists – AHFS 243208
2. Direct Vasodilators – AHFS 240820	11. Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220
3. Peripheral Adrenergic Inhibitors – AHFS 240832	12. Renin Inhibitors – AHFS 243240
4. Hypotensive Agents, Miscellaneous – AHFS 240892	13. Loop Diuretics – AHFS 402808
5. Alpha-Adrenergic Blocking Agents – AHFS 242000	14. Potassium-Sparing Diuretics – AHFS 402816
6. Beta-Adrenergic Blocking Agents – AHFS 242400	15. Thiazide Diuretics – AHFS 402820
7. Dihydropyridines – AHFS 242808	16. Thiazide-Like Diuretics – AHFS 402824
8. Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892	17. Diuretics, Miscellaneous – AHFS 402892
9. Angiotensin-Converting Enzyme Inhibitors – AHFS 243204	

New Drug REVIEWS
1. Intuniv® (Central Nervous System Agents, Miscellaneous) – AHFS 289200
2. Ulesfia® (Scabicides and Pediculicides) – AHFS 840412

\* Please note that a new drug product must be on the market for a minimum of 6 months from launch date in order to be included in a drug class review.

While we understand there is a level of coordination between members of the manufacturing industry and a provider through the normal course of business, Alabama Medicaid asks manufacturers to respect P&T Committee members' commitment to the State of Alabama by following the procedures available through the P&T policy. Also, as outlined in the P&T Committee Statement of Integrity, Committee members agree not to have ex parte contacts or discussions with manufacturers or representatives whose drugs are presented for review. This is specifically regarding drugs to be reviewed in an upcoming Medicaid P&T meeting.

As you may be aware, manufacturers whose products are scheduled for review are allowed the opportunity to provide written clinical comments for distribution to the Medicaid P&T Committee members prior to the meeting. For products slated for P&T Committee review, manufacturers are also allowed the opportunity to make brief (no more than 5 minutes) oral summary presentations of their products' clinical data to the Medicaid P&T Committee on the day of the meeting. At the initiation of the 5 minute presentation, the speaker will be required to state any financial interest in or other relationship with the manufacturer of any product(s) the speaker intends to discuss. Speakers may not solicit questions from P&T members during the oral presentation. All questions from Medicaid P&T Committee members regarding specific products and/or AHFS drug classes will be addressed by the clinical contractor or Medicaid after the clinical review of the class.

Continued on next page

**Approval for distribution of written clinical comments to P&T Committee members and approval of oral presentation summary submissions are based strictly upon the following guidelines:**

**Written Comments:**

- 1) All written comments must be e-mailed to Medicaid's Clinical Contractor, *Goold Health Systems (GHS)* at [clinical.contractor@ghsinc.com](mailto:clinical.contractor@ghsinc.com) and received no later than **Wednesday, October 20, 2010**. Submissions must include the full contact information (mailing address, phone, fax, and e-mail) of the designated manufacturer's point of contact.
- 2) Written comments should be submitted in PDF format and should be limited to one drug product per PDF file. Manufacturers wishing to provide written comments on more than one drug product must submit a separate PDF file for each product.
- 3) **Submissions are limited to 100 pages for each drug product. Submissions must be clearly labeled as "Written Comments".**
- 4) Written comments should be limited to clinical information only and **must not contain any reference to cost or general drug- or disease-specific economic information.**
- 5) Written comments must be limited to sound clinical evidence and to Food and Drug Administration (FDA)-approved indications covered under Alabama Medicaid Pharmacy benefit and not contain anecdotal content.

**Oral Presentation Summaries:**

- 1) Written notification of your intent to make an oral presentation must be e-mailed to *Goold Health Systems (GHS)* at [clinical.contractor@ghsinc.com](mailto:clinical.contractor@ghsinc.com) and received no later than **Wednesday, October 20, 2010**. Submissions must include the full contact information (mailing address, phone, fax, and e-mail) of the designated manufacturer's point of contact.
- 2) Oral presentation summaries should be submitted in PDF format and should be limited to one drug product per PDF file. Manufacturers wishing to provide an oral presentation on more than one drug product must submit a separate one-page summary, in PDF format, for each product.
- 3) Submissions are limited to a one-page summary for each drug product. (Please note: the presentation summary must be a single-sided document; references, package inserts, and any other information may be submitted but only the summary will be reviewed). **Submissions must be clearly labeled as "Oral Presentation Summary".**
- 4) Oral presentations must also be limited to clinical information only and **must not contain any reference to cost or general drug- or disease-specific economic information.**
- 5) Oral presentations must be limited to sound clinical evidence and to Food and Drug Administration (FDA)-approved indications covered under Alabama Medicaid Pharmacy benefit and not contain anecdotal content. All statistics identified for discussion must be supported by noting the source from which the information was obtained. This information does not have to be in formal reference format.

Failure to abide by all of these requirements upon submission will result in a rejection of the written comments and/or oral presentation summaries in their entirety. Manufacturers are also encouraged to submit information as soon as possible. Waiting until just days prior to the deadline for submission of these materials may not allow time for corrections and resubmission prior to the deadline. No submissions or resubmissions will be accepted after the designated deadline. At no time should representatives of the pharmaceutical manufacturing entity contact the Clinical Support Contractor, GHS, regarding this submission process. All inquires should be directed to the contact person listed below. Also, please refer to the Medicaid website ([www.medicaid.alabama.gov](http://www.medicaid.alabama.gov)) for additional information related to presentations, timelines, clinical comment submissions, and/or submission of supplemental rebate offers. Supplemental rebate offers should not be included in this submission to GHS, as these will not be reviewed by GHS nor forwarded to Alabama Medicaid. The supplemental rebate offer form is available on the Medicaid website. If you should have additional questions regarding this notice or if you have received this letter and are no longer the appropriate contact, please notify the Medicaid Pharmacy Program at (334) 353-4582.

Sincerely,



Bakeba R. Thomas, Administrator  
Pharmacy Clinical Support Unit